InvestorsObserver
×
News Home

Can Cellectar Biosciences Inc (CLRB) Stock Rise to the Top of Healthcare Sector Wednesday?

Wednesday, July 12, 2023 10:48 AM | InvestorsObserver Analysts

Mentioned in this article

Can Cellectar Biosciences Inc (CLRB) Stock Rise to the Top of Healthcare Sector Wednesday?

Cellectar Biosciences Inc (CLRB) is near the top in its sector according to InvestorsObserver. CLRB gets an overall rating of 34. That means it scores higher than 34% of stocks. Cellectar Biosciences Inc gets a 72 rank in the Healthcare sector. Healthcare is number 4 out of 11 sectors.

Overall Score - 34
CLRB has an Overall Score of 34. Find out what this means to you and get the rest of the rankings on CLRB!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Cellectar Biosciences Inc Stock Today?

Cellectar Biosciences Inc (CLRB) stock is trading at $1.82 as of 10:12 AM on Wednesday, Jul 12, a rise of $0.03, or 1.68% from the previous closing price of $1.79. The stock has traded between $1.82 and $1.87 so far today. Volume today is below average. So far 2,658 shares have traded compared to average volume of 33,312 shares. Click Here to get the full Stock Report for Cellectar Biosciences Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App